Gastroenterology Research and Practice / 2016 / Article / Tab 2

Clinical Study

Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study

Table 2

Clinical characteristics of patients with ulcerative colitis (UC) treated with tacrolimus (TAC) group who were randomly assigned to maintenance therapy with TAC, AZA, or TAC + AZA.

TAC ()AZA ()TAC + AZA () value

Male/female9/47/66/8NS
Age (years) 49.7 ± 16.442.4 ± 14.339.4 ± 15.3NS
Duration of UC (years) 7.3 ± 7.711.3 ± 107.7 ± 8.2NS
Follow-up time (days) 693 ± 3591205 ± 349806 ± 362<0.05
Pancolitis/left-sided colitis9/47/68/6NS
Past AZA therapy (yes/no)9/49/48/6NS
Baseline CAI 13.7 ± 3.713.6 ± 3.013.5 ± 2.5NS
Time to reach target blood TAC level (days) 3.6 ± 2.65.0 ± 2.53.9 ± 2.5NS
TAC treatment time (days) 402 ± 16787 ± 12240 ± 166

Baseline Hb (g/dL) 10.8 ± 2412.1 ± 2.313.3 ± 2.1NS
Baseline CRP (mg/dL) 2.2 ± 2.73.7 ± 5.21.1 ± 0.7NS

Mayo 3.0 ± 0.03.0 ± 0.03.0 ± 0.0NS
UCEIS 6.3 ± 1.16.6 ± 1.86.4 ± 1.1NS
EAI 13.5 ± 2.113.9 ± 1.613.6 ± 1.5NS

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.